Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular ...

Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and ...

A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...

Ozempic, a semaglutide drug originally developed for type-2 diabetes, has been in the news as a fast-track weight-loss solution. A former AIIMS dietitian, took to X (twitter) to reveal that while ...

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes ...

Share on Pinterest A new study finds that GLP-1 drugs’ heart health benefits may not be solely due to weight loss. The Good Brigade/Getty Images As the popularity of GLP-1 receptor agonists for weight ...

Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...

A large meta-analysis, published in Diabetology & Metabolic Syndrome, suggested that semaglutide improved several liver-related and metabolic outcomes in people with or at risk of developing MASH, ...

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, ...

Please provide your email address to receive an email when new articles are posted on . Data from SURMOUNT-OSA and a prespecified analysis of the SELECT trial were among the biggest obesity studies in ...

BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress to cirrhosis and hepatocellular carcinoma, but strategies for treating MASH are lacking. Resmetirom ...